[{"id":"044ad04e-9242-4d5c-b71d-62ab6ac33aad","acronym":"STEM","url":"https://clinicaltrials.gov/study/NCT02970682","created_at":"2021-01-18T14:36:07.066Z","updated_at":"2024-07-02T16:36:58.181Z","phase":"Phase 2","brief_title":"SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer","source_id_and_acronym":"NCT02970682 - STEM","lead_sponsor":"Evgen Pharma","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • Sulforadex (sulforafan alfadex)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-07-12"}]